10-QPeriod: Q3 FY2010

ALNYLAM PHARMACEUTICALS, INC. Quarterly Report for Q3 Ended Sep 30, 2010

Filed November 4, 2010For Securities:ALNY

Summary

This 10-Q filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY) for the period ending September 30, 2010, provides investors with an unaudited look at the company's financial position and operational results for the third quarter and the first nine months of 2010. As a clinical-stage biopharmaceutical company, ALNY's financial performance is heavily influenced by its research and development activities, significant operating losses, and its reliance on cash reserves and potential future financing. Investors should pay close attention to the company's cash burn rate, the progress of its drug development pipeline, and any updates on strategic partnerships or collaborations, as these factors will be critical to its long-term viability and potential for future revenue generation.

Financial Highlights

39 data points
Beta

Revenue

$27.67M

Net Income

-$9.63M

-34.8% Net Margin

EPS (Diluted)

$-0.23

Total Assets

$412.61M

Cash & Equivalents

$46.88M

Free Cash Flow

-$25.11M

Financial Statements
Beta
Revenue$27.67M
R&D Expenses$27.47M
Operating Expenses$36.40M
Operating Income-$8.73M
Net Income-$9.63M
EPS (Basic)$-0.23

Key Highlights

  • 1The company's financial statements are unaudited for the nine months ending September 30, 2010, reflecting the typical reporting for interim periods.
  • 2ALNY continues to operate at a significant loss, characteristic of a clinical-stage biopharmaceutical company heavily investing in R&D.
  • 3The filing includes detailed unaudited condensed consolidated balance sheets, statements of operations and comprehensive loss, and cash flows, providing insight into the company's financial health.
  • 4Management's Discussion and Analysis of Financial Condition and Results of Operations will be a key section for understanding the drivers of the company's performance and its outlook.
  • 5Risk factors section (Item 1A) is crucial for understanding potential challenges and uncertainties facing the company, including regulatory, clinical, and financial risks.
  • 6The company is actively engaged in research and development, which is expected to be the primary driver of expenses and future growth potential.

Frequently Asked Questions

As of September 30, 2010, ALNY's financial health is characterized by ongoing operating losses typical of a clinical-stage biopharmaceutical company. The condensed consolidated balance sheets will detail cash and cash equivalents, which are critical for funding ongoing research and development activities. Investors should refer to the Statements of Cash Flows to understand the cash burn rate and the sources of funding.

ALNY's operating losses are primarily driven by substantial investments in research and development (R&D). This includes costs associated with drug discovery, pre-clinical studies, clinical trials, and personnel engaged in these activities. The unaudited Statements of Operations will provide a breakdown of revenues (if any) and operating expenses.

Item 1A, 'Risk Factors,' is the primary section detailing the significant risks. These typically include, but are not limited to, the inherent risks of drug development (e.g., clinical trial failures, regulatory approvals), dependence on future financing, competition from other pharmaceutical companies, intellectual property protection, and the ability to successfully commercialize any approved therapies.

Investors can find detailed financial performance information in the 'Financial Statements (Unaudited)' section, specifically the 'Condensed Consolidated Statements of Operations and Comprehensive Loss' for the three and nine months ended September 30, 2010. Additionally, the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' (Item 2) will provide narrative context and explanations for the reported results.